Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...

Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the palazestrant plus ribociclib combination trial.

Dr. Maccecchini will discuss the Company’s latest advancements, highlighting the progress of the pivotal Phase 3 trial in early ... disease-modifying treatment. Oppenheimer's Annual Healthcare ...

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini ...

Oppenheimer's decision to downgrade the stock rating reflects the uncertainty surrounding the future of the BEACON trial and the potential impact on Pliant Therapeutics' prospects. The analysts have ...

Oppenheimer analysts, led by Matthew Biegler, downgraded the company’s stock from Outperform to Perform in light of these developments. The adjustment comes after the trial’s failure to ...